PL2233156T3 - Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych - Google Patents
Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznychInfo
- Publication number
- PL2233156T3 PL2233156T3 PL10006638T PL10006638T PL2233156T3 PL 2233156 T3 PL2233156 T3 PL 2233156T3 PL 10006638 T PL10006638 T PL 10006638T PL 10006638 T PL10006638 T PL 10006638T PL 2233156 T3 PL2233156 T3 PL 2233156T3
- Authority
- PL
- Poland
- Prior art keywords
- carriers
- pharmaceutical conjugates
- aprotinin polypeptides
- aprotinin
- polypeptides
- Prior art date
Links
- 108010039627 Aprotinin Proteins 0.000 title 1
- 229960004405 aprotinin Drugs 0.000 title 1
- 239000000969 carrier Substances 0.000 title 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69937505P | 2005-07-15 | 2005-07-15 | |
| US75853206P | 2006-01-13 | 2006-01-13 | |
| EP10006638.0A EP2233156B1 (en) | 2005-07-15 | 2006-07-14 | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates |
| EP06761127A EP1907009A4 (en) | 2005-07-15 | 2006-07-14 | USE OF APROTININ POLYPEPTIDES AS CARRIER IN PHARMACEUTICAL CONJUGATES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2233156T3 true PL2233156T3 (pl) | 2013-09-30 |
Family
ID=37668389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10006638T PL2233156T3 (pl) | 2005-07-15 | 2006-07-14 | Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US8969310B2 (https=) |
| EP (4) | EP1907009A4 (https=) |
| JP (3) | JP5436856B2 (https=) |
| CN (1) | CN101262890B (https=) |
| AU (1) | AU2006272405B2 (https=) |
| BR (1) | BRPI0613005A8 (https=) |
| CA (1) | CA2614687C (https=) |
| DK (2) | DK2433653T3 (https=) |
| ES (2) | ES2744225T3 (https=) |
| HR (1) | HRP20130720T1 (https=) |
| PL (1) | PL2233156T3 (https=) |
| PT (1) | PT2233156E (https=) |
| RU (2) | RU2422143C2 (https=) |
| SI (1) | SI2233156T1 (https=) |
| WO (1) | WO2007009229A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004060403A2 (en) | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| US7906625B2 (en) | 2005-01-24 | 2011-03-15 | Amgen Inc. | Humanized anti-amyloid antibody |
| US20090016959A1 (en) * | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| RU2408605C2 (ru) * | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA3000520C (en) | 2005-08-24 | 2023-04-04 | Immunogen, Inc. | Process for preparing antibody maytansinoid conjugates |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| PT2164866E (pt) * | 2007-05-29 | 2014-08-04 | Angiochem Inc | Polipéptidos de tipo aprotinina para administrar agentes conjugados com os mesmos aos tecidos |
| AU2008255556B2 (en) * | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| BRPI0821310A2 (pt) * | 2007-12-20 | 2015-06-16 | Angiochem Inc | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
| EP2235058A2 (en) | 2007-12-21 | 2010-10-06 | Amgen, Inc | Anti-amyloid antibodies and uses thereof |
| MX355683B (es) * | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| WO2010043049A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2740316A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CA2745524C (en) * | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| DE102009006228A1 (de) | 2009-01-27 | 2010-07-29 | Epo Experimentelle Pharmakologie & Onkologie Berlin-Buch Gmbh | Liposomale Zusammensetzung zur Behandlung von Hirnmetastasen |
| JP2010229122A (ja) * | 2009-03-06 | 2010-10-14 | Kumamoto Univ | 抗癌剤、医薬、及び癌疾患の検査薬 |
| MX2011011023A (es) * | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| SG10201810743WA (en) | 2009-06-03 | 2018-12-28 | Immunogen Inc | Conjugation methods |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| JP2013530993A (ja) | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
| WO2012037687A1 (en) * | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| CN102085157B (zh) * | 2011-01-27 | 2012-02-01 | 中国水产科学研究院黄海水产研究所 | 扇贝抗氧化肽纳米脂质体及其制备方法 |
| CN102614524A (zh) * | 2011-02-01 | 2012-08-01 | 复旦大学 | 低密度脂蛋白受体相关蛋白配体多肽修饰的脑肿瘤靶向基因递释复合物 |
| ME03353B (me) | 2011-03-29 | 2019-10-20 | Immunogen Inc | Priprema konjugata antitela i majtanzinoida jednostepenim postupkom |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| RU2661083C2 (ru) | 2012-10-04 | 2018-07-11 | Иммуноджен, Инк. | Использование пвдф-мембраны для очистки конъюгатов клеточно-связывающий агент - цитотоксический агент |
| JP2015535523A (ja) * | 2012-11-12 | 2015-12-14 | アンジオケム インコーポレーテッド | アプロチニン由来ポリペプチド−抗体コンジュゲート |
| JP6254692B2 (ja) * | 2013-07-03 | 2017-12-27 | ジ アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | 認知機能不全を治療するための方法 |
| EP3018143B1 (en) | 2013-07-03 | 2019-05-29 | Seoul National University R&DB Foundation | Chicken antibody transformed into cysteine and site-specific conjugation using same |
| JP6666899B2 (ja) | 2014-07-21 | 2020-03-18 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニヴァーシティー オブ アリゾナ | Ａｎｇ−（１−７）誘導体オリゴペプチド、ならびにそれを使用および作製するための方法 |
| US10183055B2 (en) | 2014-07-21 | 2019-01-22 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ang-(1-7) derivative oligopeptides for the treatment of pain and other indications |
| GB201502447D0 (en) | 2015-02-13 | 2015-04-01 | Univ Liverpool | Method and apparatus for sample analysis |
| EP3307326B9 (en) | 2015-06-15 | 2021-02-24 | Angiochem Inc. | Methods for the treatment of leptomeningeal carcinomatosis |
| US12419832B2 (en) | 2018-01-29 | 2025-09-23 | Cognos Therapeutics, Inc. | Intratumoral delivery of bortezomib |
| CN111529716B (zh) * | 2020-06-02 | 2021-05-28 | 南方医科大学 | 一种多肽-紫杉醇偶联物及其应用 |
Family Cites Families (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US508697A (en) * | 1893-11-14 | Jar or bottle receiver | ||
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| ES526626A0 (es) * | 1983-10-07 | 1984-10-01 | Jumberca Sa | Mejoras en los alimentadores de hilo para telares circulares de genero de punto dotados de dispositivos listadores. |
| AU599373B2 (en) | 1986-03-13 | 1990-07-19 | Biotechnology Australia Proprietary Limited | Method of assay of inhibin |
| US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| US4904768A (en) * | 1987-08-04 | 1990-02-27 | Bristol-Myers Company | Epipodophyllotoxin glucoside 4'-phosphate derivatives |
| GB2208511A (en) | 1987-08-07 | 1989-04-05 | Bayer Ag | Variants of bovine pancreatic trypsin inhibitor produced by recombinant dna technology |
| US4942184A (en) | 1988-03-07 | 1990-07-17 | The United States Of America As Represented By The Department Of Health And Human Services | Water soluble, antineoplastic derivatives of taxol |
| US5632990A (en) | 1988-04-22 | 1997-05-27 | Cancer Research Campaign Tech. Ltd. | Treatment for tumors comprising conjugated antibody A5B7 and a prodrug |
| US5258499A (en) * | 1988-05-16 | 1993-11-02 | Vestar, Inc. | Liposome targeting using receptor specific ligands |
| US5028697A (en) | 1988-08-08 | 1991-07-02 | Eli Lilly And Company | Cytotoxic antibody conjugates of hydrazide derivatized methotrexate analogs via simple organic linkers |
| US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
| US5223409A (en) * | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5948634A (en) * | 1988-12-21 | 1999-09-07 | The General Hospital Coporation | Neural thread protein gene expression and detection of alzheimer's disease |
| DE3912638A1 (de) | 1989-04-18 | 1990-10-31 | Bayer Ag | Gentechnologisch hergestellte homologe des alzheimer protease inhibitors, wirtstaemme sowie expressionsvektoren fuer ihre herstellung und ihre verwendung als arzneimittel |
| US6020145A (en) * | 1989-06-30 | 2000-02-01 | Bristol-Myers Squibb Company | Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96 |
| US6475781B1 (en) | 1990-05-17 | 2002-11-05 | Dana-Farber Cancer Institute, Inc. | Trans-dominant suppressor genes for oligomeric proteins |
| US5714167A (en) | 1992-06-15 | 1998-02-03 | Emisphere Technologies, Inc. | Active agent transport systems |
| US6495513B1 (en) | 1991-03-11 | 2002-12-17 | Curis, Inc. | Morphogen-enhanced survival and repair of neural cells |
| US5955444A (en) | 1991-08-09 | 1999-09-21 | Massachusetts Institute Of Technology | Method of inhibiting abnormal tau hyper phosphorylation in a cell |
| US5627270A (en) * | 1991-12-13 | 1997-05-06 | Trustees Of Princeton University | Glycosylated steroid derivatives for transport across biological membranes and process for making and using same |
| GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
| EP0671944A4 (en) | 1992-09-25 | 1996-07-24 | Corvas Int Inc | TISSUE VIA-THROMBOPLASTIN FACTOR COMPLEX INHIBITORS DERIVED FROM A BOVINE PANCREATIC TRYPSIN INHIBITOR. |
| EP0599303A3 (en) * | 1992-11-27 | 1998-07-29 | Takeda Chemical Industries, Ltd. | Peptide conjugate |
| IL107950A (en) | 1992-12-15 | 2001-04-30 | Upjohn Co | 7β, 8β - METHANO-TAXOLS, THEIR PREPARATION AND ANTINEOPLASTIC PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| WO1994019692A1 (en) * | 1993-02-18 | 1994-09-01 | The General Hospital Corporation | Alzheimer's disease therapeutics |
| EP0820466A2 (en) | 1995-04-04 | 1998-01-28 | Advanced Bioconcept Inc. | Fluorescent peptides |
| KR19990008458A (ko) | 1995-05-08 | 1999-01-25 | 쉬어러 피터 알. | 쿠니츠(kunitz) 타입 프로테아제 억제 물질 |
| ZA963619B (en) | 1995-05-08 | 1996-11-22 | Scios Inc | Protease inhibitor peptides |
| WO1996039183A1 (en) | 1995-05-31 | 1996-12-12 | Fred Hutchinson Cancer Research Center | Compositions and methods for targeted delivery of effector molecules |
| US5780265A (en) | 1995-06-05 | 1998-07-14 | Genentech, Inc. | Kunitz type plasma kallikrein inhibitors |
| US5665702A (en) | 1995-06-06 | 1997-09-09 | Biomeasure Incorporated | Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides |
| JPH11507535A (ja) | 1995-06-07 | 1999-07-06 | イムクローン システムズ インコーポレイテッド | 腫瘍の成長を抑制する抗体および抗体フラグメント類 |
| JP3469584B2 (ja) | 1996-03-11 | 2003-11-25 | バイエル コーポレイション | ヒト ビクニン |
| AU2409397A (en) | 1996-04-24 | 1997-11-12 | Rijksuniversiteit Te Groningen | A prokaryotic protein having functional and structural homology with the uman p-glycoprotein encoded by the mdr-1 gene, nucleic acids encoding and cells expressing said protein |
| AU729643B2 (en) | 1996-05-01 | 2001-02-08 | Antivirals Inc. | Polypeptide conjugates for transporting substances across cell membranes |
| US6056973A (en) * | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
| JP2001503396A (ja) | 1996-10-11 | 2001-03-13 | アルザ コーポレイション | 治療用リポソーム組成物および方法 |
| US5948750A (en) | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| JP4116683B2 (ja) | 1997-02-28 | 2008-07-09 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 徐放性局所送達製剤 |
| AU6682598A (en) * | 1997-03-04 | 1998-09-22 | Bio-Technology General Corporation | Isolation of tissue specific peptide ligands and their use for targeting pharmaceuticals to organs |
| US6126965A (en) * | 1997-03-21 | 2000-10-03 | Georgetown University School Of Medicine | Liposomes containing oligonucleotides |
| CN1263473A (zh) * | 1997-05-21 | 2000-08-16 | 利兰·斯坦福青年大学托管委员会 | 增加跨生物膜转运的组合物和方法 |
| US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
| US6093692A (en) * | 1997-09-25 | 2000-07-25 | The University Of Southern California | Method and compositions for lipidization of hydrophilic molecules |
| US6475481B2 (en) | 1997-11-18 | 2002-11-05 | Canji Inc | Purging of stem cell products |
| WO1999026657A1 (en) | 1997-11-25 | 1999-06-03 | Musc Foundation For Research Development | Inhibitors of nitric oxide synthase |
| US5981564A (en) * | 1998-07-01 | 1999-11-09 | Universite Laval | Water-soluble derivatives of paclitaxel, method for producing same and uses thereof |
| GB9814527D0 (en) * | 1998-07-03 | 1998-09-02 | Cyclacel Ltd | Delivery system |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| US5922754A (en) * | 1998-10-02 | 1999-07-13 | Abbott Laboratories | Pharmaceutical compositions containing paclitaxel |
| MXPA01008699A (es) * | 1999-02-24 | 2002-06-21 | Uab Research Foundation | Derivados de taxano para terapia de cancer dirigida. . |
| US6713454B1 (en) | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6136846A (en) | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
| DE19953696A1 (de) * | 1999-11-09 | 2001-05-10 | Alexander Cherkasky | Selektive proteolytische Synzyme (SPS) |
| CA2307393A1 (en) * | 2000-05-01 | 2001-11-01 | The University Of British Columbia | Ginsenoside chemotherapy |
| CA2355334A1 (en) | 2000-10-16 | 2002-04-16 | Procyon Biopharma Inc. | Pharmaceutical preparations and methods for inhibiting tumors |
| US6919370B2 (en) | 2000-11-28 | 2005-07-19 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof |
| US7115565B2 (en) * | 2001-01-18 | 2006-10-03 | Pharmacia & Upjohn Company | Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability |
| CA2441484A1 (en) * | 2001-03-23 | 2002-10-03 | Napro Biotherapeutics, Inc. | Molecular conjugates for use in treatment of cancer |
| WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| AU2002322720B2 (en) * | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US20040161776A1 (en) | 2001-10-23 | 2004-08-19 | Maddon Paul J. | PSMA formulations and uses thereof |
| US7192921B2 (en) | 2001-11-08 | 2007-03-20 | The Burnham Institute | Peptides that home to tumor lymphatic vasculature and methods of using same |
| GEP20063806B (en) * | 2001-12-20 | 2006-04-25 | Bristol Myers Squibb Co | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| RU2196604C1 (ru) * | 2001-12-21 | 2003-01-20 | Северин Евгений Сергеевич | Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе |
| AU2003209577A1 (en) * | 2002-02-07 | 2003-09-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Amino acid sequences capable of facilitating penetration across a biological barrier |
| US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
| JP2005537244A (ja) | 2002-06-28 | 2005-12-08 | ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド | 療法化合物の粘膜搬送を増進させるための、上皮接合部接着分子の生理機能を調節する組成物および方法 |
| US7829694B2 (en) | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
| US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
| US20040102369A1 (en) * | 2002-11-27 | 2004-05-27 | The Regents Of The University Of California | Transport of basic fibroblast growth factor across the blood brain barrier |
| WO2004060403A2 (en) * | 2003-01-06 | 2004-07-22 | Angiochem Inc. | Aprotinin and anglos as carriers across the blood-brain barrier |
| NZ542791A (en) * | 2003-04-08 | 2008-04-30 | Biotempt Bv | Compositions for mucosal and oral administration comprising HCG fragments |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| AU2003286870A1 (en) | 2003-06-05 | 2005-01-04 | Salk Institute For Biological Studies | Targeting polypeptides to the central nervous system |
| EP1638605B1 (en) | 2003-06-20 | 2014-01-08 | Raptor Pharmaceutical, Inc. | Delivery of therapeutic compounds to the brain and other tissues |
| US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
| KR20060036476A (ko) | 2003-08-08 | 2006-04-28 | 가부시키가이샤 티슈 타겟팅 쟈판 | 뇌 이동 활성을 가지는 폴리펩티드 및 그 이용 |
| EP1663278A4 (en) * | 2003-08-28 | 2009-07-29 | Biorexis Pharmaceutical Corp | EPO MIMETIC PEPTIDES AND FUSION PROTEINS |
| US20050058702A1 (en) | 2003-09-17 | 2005-03-17 | Ben-Sasson Shmuel A. | Compositions capable of facilitating penetration across a biological barrier |
| US20050208095A1 (en) | 2003-11-20 | 2005-09-22 | Angiotech International Ag | Polymer compositions and methods for their use |
| US7208174B2 (en) | 2003-12-18 | 2007-04-24 | Hoffmann-La Roche Inc. | Liposome compositions |
| WO2006091231A2 (en) * | 2004-07-21 | 2006-08-31 | Ambrx, Inc. | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
| EP1771467A2 (en) | 2004-07-26 | 2007-04-11 | Asterion Limited | Linkers |
| CA2580189C (en) | 2004-09-29 | 2013-05-21 | Children's Memorial Hospital | Sirna-mediated gene silencing of alpha synuclein |
| RU2408605C2 (ru) * | 2005-02-18 | 2011-01-10 | Анджиокем Инк. | Полипептид, способный преодолевать гематоэнцефалический барьер, и его конъюгат |
| KR20070114753A (ko) | 2005-02-18 | 2007-12-04 | 아브락시스 바이오사이언스 인크. | 치료제의 조합 및 투여 방식, 및 조합 요법 |
| US20090016959A1 (en) | 2005-02-18 | 2009-01-15 | Richard Beliveau | Delivery of antibodies to the central nervous system |
| EP1888121A2 (en) * | 2005-05-12 | 2008-02-20 | Tapestry Pharmaceuticals, Inc. | Anticancer targeted conjugates comprising a succinyl or glutaryl linker |
| US8877714B2 (en) | 2005-06-14 | 2014-11-04 | Raptor Pharmaceutical Inc. | Compositions comprising receptor-associated protein (RAP) variants specific for LRP2 and uses thereof |
| ES2744225T3 (es) | 2005-07-15 | 2020-02-24 | Angiochem Inc | Uso de polipéptidos de aprotinina como portadores en conjugados farmacéuticos |
| CA2615617A1 (en) * | 2005-07-19 | 2007-01-25 | The Board Of Trustees Of The University Of Illinois | Transport agents for crossing the blood-brain barrier and into brain cancer cells, and methods of use thereof |
| GB0517092D0 (en) | 2005-08-19 | 2005-09-28 | Novartis Ag | New compositions containing taxane derivatives |
| JP2009507852A (ja) | 2005-09-08 | 2009-02-26 | エムディーアールエヌエー，インコーポレイテッド | リボ核酸の細胞への送達用医薬組成物 |
| EP1945240B1 (en) | 2005-09-16 | 2016-12-28 | Raptor Pharmaceutical Inc | Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof |
| US8053569B2 (en) | 2005-10-07 | 2011-11-08 | Armagen Technologies, Inc. | Nucleic acids encoding and methods of producing fusion proteins |
| WO2007053696A2 (en) | 2005-11-01 | 2007-05-10 | Alnylam Pharmaceuticals, Inc. | Rnai inhibition of influenza virus replication |
| AR054215A1 (es) | 2006-01-20 | 2007-06-13 | Eriochem Sa | Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit |
| CN101511868B (zh) | 2006-07-24 | 2013-03-06 | 比奥雷克西斯制药公司 | 毒蜥外泌肽融合蛋白 |
| EP2063905B1 (en) | 2006-09-18 | 2014-07-30 | Raptor Pharmaceutical Inc | Treatment of liver disorders by administration of receptor-associated protein (rap)-conjugates |
| JP2010506860A (ja) | 2006-10-19 | 2010-03-04 | アンジオケム，インコーポレーテッド | Ｐ−糖タンパク質機能を刺激するための化合物およびその使用 |
| AU2008255556B2 (en) | 2007-05-29 | 2014-08-07 | Angiochem, Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| US8802631B2 (en) | 2007-09-17 | 2014-08-12 | Ludwig Institute For Cancer Research Ltd. | Peptides and methods for the treatment of gliomas and other cancers |
| WO2009070597A2 (en) | 2007-11-26 | 2009-06-04 | Armagen Technologies, Inc. | Fusion proteins for delivery of gdnf to the cns |
| BRPI0821310A2 (pt) | 2007-12-20 | 2015-06-16 | Angiochem Inc | Conjugados polipeptídeos-ácido nucleico e usos dos mesmos |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| JP2011514160A (ja) | 2008-02-21 | 2011-05-06 | バーナム インスティテュート フォー メディカル リサーチ | Ｃ末端エレメントを有するペプチドおよびタンパク質に関する方法および組成物 |
| MX355683B (es) | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| WO2010043049A1 (en) * | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Etoposide and doxorubicin conjugates for drug delivery |
| CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
| EP2370472A4 (en) | 2008-12-05 | 2013-04-24 | Angiochem Inc | LEPTIN AND LEPTIN ANALOGUE CONJUGATES AND ITS USES |
| CN102348723A (zh) | 2008-12-05 | 2012-02-08 | 安吉奥开米公司 | 肽治疗剂轭合物及其应用 |
| US8853353B2 (en) | 2008-12-17 | 2014-10-07 | Angiochem, Inc. | Membrane type-1 matrix metalloprotein inhibitors and uses thereof |
| MX2011011023A (es) * | 2009-04-20 | 2012-01-20 | Angiochem Inc | Tratamiento de cancer de ovarios usando un agente anti-cancer conjugado con un analogo de angiopep-2. |
| US20100284921A1 (en) | 2009-05-08 | 2010-11-11 | Temple University - Of The Commonwealth System Of Higher Education | Targeted nanoparticles for intracellular cancer therapy |
| CN103819564A (zh) | 2009-06-11 | 2014-05-28 | 安吉奥开米公司 | 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白 |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| EP3000481A3 (en) | 2009-07-14 | 2016-05-11 | Mayo Foundation for Medical Education and Research | Peptide-mediated non-covalent delivery of active agent agents across the blood brain barrier |
| AU2010305284A1 (en) | 2009-10-06 | 2012-05-03 | Angiochem Inc. | Compositions and methods for the transport of therapeutic agents |
| US8530429B2 (en) | 2009-11-24 | 2013-09-10 | Arch Cancer Therapeutics, Inc. | Brain tumor targeting peptides and methods |
| WO2011153642A1 (en) | 2010-06-10 | 2011-12-15 | Angiochem Inc. | Leptin and leptin analog conjugates and fusion proteins and uses thereof |
| JP2013530993A (ja) | 2010-07-02 | 2013-08-01 | アンジオケム インコーポレーテッド | 治療用コンジュゲートのための短く且つｄ−アミノ酸を含有するポリペプチドおよびその使用 |
| WO2012037687A1 (en) | 2010-09-23 | 2012-03-29 | Angiochem Inc. | Therapeutic polypeptides and uses thereof |
| EP2640359A4 (en) | 2010-11-18 | 2015-11-04 | Gen Hospital Corp | NOVEL COMPOSITIONS AND USES OF HYPOTENSE AGENTS IN THE TREATMENT OF CANCER |
| WO2013056096A1 (en) | 2011-10-13 | 2013-04-18 | Angiochem Inc. | Polypeptide-opioid conjugates and uses thereof |
| CN104145015A (zh) | 2011-12-01 | 2014-11-12 | 安吉奥开米公司 | 靶向的溶酶体酶化合物 |
| BR112014013250A2 (pt) | 2011-12-01 | 2019-09-24 | Angiochem Inc | compostos com enzima alvo e usos dos mesmos |
| AU2013273894A1 (en) | 2012-06-15 | 2015-02-05 | Angiochem Inc. | Targeted iduronidase compounds |
| US20160106856A1 (en) | 2012-08-14 | 2016-04-21 | Angiochem Inc. | Conjugates including an antibody moiety, a polypeptide that traverses the blood-brain barrier, and a cytotoxin |
| JP2015526434A (ja) | 2012-08-14 | 2015-09-10 | アンジオケム インコーポレーテッド | ペプチド−デンドリマーコンジュゲート及びその使用 |
| JP2015535523A (ja) | 2012-11-12 | 2015-12-14 | アンジオケム インコーポレーテッド | アプロチニン由来ポリペプチド−抗体コンジュゲート |
| GB201220474D0 (en) | 2012-11-14 | 2012-12-26 | Sagetis Biotech Sl | Polypeptides |
| JP2015536658A (ja) | 2012-11-30 | 2015-12-24 | アンジオケム インコーポレーテッド | 標的化イズロン酸−２−スルファターゼ化合物 |
| HK1179821A2 (en) | 2013-05-28 | 2013-10-04 | 捷迅视讯器材有限公司 | High voltage discharge protection device and radio frequency transmission apparatus using the same |
| WO2014194428A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted heparan sulfatase compounds |
| WO2014194429A1 (en) | 2013-06-06 | 2014-12-11 | Angiochem Inc. | Targeted enzyme compounds and uses thereof |
-
2006
- 2006-07-14 ES ES11010125T patent/ES2744225T3/es active Active
- 2006-07-14 PT PT100066380T patent/PT2233156E/pt unknown
- 2006-07-14 BR BRPI0613005A patent/BRPI0613005A8/pt not_active Application Discontinuation
- 2006-07-14 WO PCT/CA2006/001165 patent/WO2007009229A1/en not_active Ceased
- 2006-07-14 JP JP2008520685A patent/JP5436856B2/ja not_active Expired - Fee Related
- 2006-07-14 EP EP06761127A patent/EP1907009A4/en not_active Withdrawn
- 2006-07-14 AU AU2006272405A patent/AU2006272405B2/en not_active Ceased
- 2006-07-14 EP EP10006638.0A patent/EP2233156B1/en not_active Not-in-force
- 2006-07-14 EP EP11010125.0A patent/EP2433653B1/en active Active
- 2006-07-14 EP EP11010071A patent/EP2471555A3/en not_active Withdrawn
- 2006-07-14 DK DK11010125.0T patent/DK2433653T3/da active
- 2006-07-14 ES ES10006638T patent/ES2424242T3/es active Active
- 2006-07-14 RU RU2008105677/15A patent/RU2422143C2/ru active
- 2006-07-14 CN CN200680033365.8A patent/CN101262890B/zh not_active Expired - Fee Related
- 2006-07-14 SI SI200631629T patent/SI2233156T1/sl unknown
- 2006-07-14 DK DK10006638.0T patent/DK2233156T3/da active
- 2006-07-14 CA CA2614687A patent/CA2614687C/en not_active Expired - Fee Related
- 2006-07-14 PL PL10006638T patent/PL2233156T3/pl unknown
-
2007
- 2007-05-30 US US11/807,917 patent/US8969310B2/en active Active
-
2011
- 2011-04-19 RU RU2011115418/15A patent/RU2011115418A/ru not_active Application Discontinuation
-
2012
- 2012-10-18 JP JP2012230853A patent/JP2013047249A/ja not_active Withdrawn
-
2013
- 2013-08-01 HR HRP20130720TT patent/HRP20130720T1/hr unknown
-
2015
- 2015-03-02 US US14/635,856 patent/US9713646B2/en not_active Expired - Fee Related
- 2015-06-03 JP JP2015112969A patent/JP2015163641A/ja active Pending
-
2017
- 2017-06-30 US US15/639,758 patent/US20180221497A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130720T1 (en) | Use of aprotinin polypeptides as carriers in pharmaceutical conjugates | |
| LT1912671T (lt) | Vaisto konjugatai, turintys gliukoronido linkerį | |
| IL186959A0 (en) | Peptides and pharmaceutical compositions containing the same | |
| IL177480A0 (en) | Pharmaceutical composition | |
| IL186336A0 (en) | Pharmaceutical composition | |
| IL185308A0 (en) | Replikin peptides and uses thereof | |
| IL221395A0 (en) | Pharmaceutical compositions comprising alpha ketoamide derivatives and uses thereof | |
| EP1976864A4 (en) | NEW PEPTIDE AND ITS USE | |
| EP1890677A4 (en) | PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
| PL2046830T3 (pl) | Polipeptydy CSF3R i ich zastosowania | |
| GB0516069D0 (en) | Pharmaceutical and use thereof | |
| HU0401177D0 (en) | Pharmaceutical composition | |
| GB0621513D0 (en) | Novel polypeptides and uses thereof | |
| GB2411355B (en) | Pharmaceutical composition | |
| GB0607798D0 (en) | Novel polypeptides and use thereof | |
| GB0425255D0 (en) | Pharmaceutical composition | |
| ZA200701932B (en) | Pharmaceutical composition | |
| ZA200701931B (en) | Pharmaceutical composition | |
| GB0526120D0 (en) | Therapeutic peptides | |
| GB0517043D0 (en) | Improvements in pharmaceutical compositions | |
| GB0516571D0 (en) | Novel polypeptides and uses thereof | |
| GB0402799D0 (en) | Pharmaceutical composition | |
| GB0515573D0 (en) | Improvements in pharmaceutical compositions | |
| GB0508767D0 (en) | Pharmaceutical preparations and their uses | |
| GB0511801D0 (en) | Pharmaceutical composition |